Evidence map›Paper›PMID 30867024›Full record

ArticleParasites & vectors2019

Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.

Kun Yin, Guihua Zhao, Chao Xu, Xiao Qiu, Biwei Wen, Hui Sun, Gongzhen Liu, Ye Liu, Qingsong Zhao, Qingkuan Wei and 3 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Therapeutic Antitoxoplasmosis Potential ofJournal of tropical medicine · 2026
    Article
  2. Article
  3. Article
  4. Toxoplasma gondii vaccine candidates: a concise review.Irish journal of medical science · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kun YinShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China. yinkun0326@163.com.
Guihua ZhaoShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Chao XuShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Xiao QiuJining No.1 People's Hospital, Jining, 272000, China.
Biwei WenDepartment of Obstetrics and Gynecology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
Hui SunShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Gongzhen LiuShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Ye LiuJining No.1 People's Hospital, Jining, 272000, China.
Qingsong ZhaoJining No.1 People's Hospital, Jining, 272000, China.
Qingkuan WeiShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Bingcheng HuangShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Ge YanShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China.
Jianping CaoShandong Academy of Medical Sciences, Shandong Institute of Parasitical Disease, Jining, 272033, China. caojpcdc@163.com.
Shandong First Medical University · CNJining First People's Hospital · CNChanghai Hospital · CNNational Institute for Parasitic Diseases · CN

Funding

Natural Science Foundation of Shandong Province BS2013SW015Natural Science Foundation of Shandong Province ZR2018LH016Open Research Foundation of Key Laboratory for Parasitic Disease WSBKTKT201503Young Scientists Fund 31300617Young Scientists Fund 81702026
6 · The paper itself

Abstract

backgroundRhoptry protein 18 (ROP18) is a key virulence factor of Toxoplasma gondii. The host's immune responses mediated by immune-related GTPases (IRGs) could be blocked by ROP18's kinase activity. ROP18 also interacts with various substrates, such as activating transcription factor 6 beta (ATF6β) and affects multiple physiological functions within host cells, thereby inducing intense virulence. In this study, competitive inhibitors targeted to ROP18 were subjected to virtual screening based on the principle of structure-based drug design (SBDD).

methodsThe preparation of the ROP18 structure was conducted using the "Structure Prepare" function of Molecular Operating Environment (MOE) software. The ATP-binding pocket was selected as the starting point for virtual screening. Construction of the pharmacophore model used Extended Hückel Theory (EHT) half-quantitative measurement and construction, as well as the characteristics of Type I kinase inhibitors. The pharmacophore model of ROP18 was imported into the Specs database for small molecule similarity screening using EHT pharmacophore measurement. Hit compounds were selected using the functions of London dG and generalized-born volume integral/weighted surface area (GBVI/WSA) scoring. The top 100 hits were analyzed by molecular docking and structure activity relationships (SAR) analysis.

resultsThe final pharmacophore comprised three typical characteristics: three hydrogen bond acceptors/donors, two ring aromatic features occupying the hydrophobic core, and one cation group feature targeted to the terminus of ATP. A total of 1314 hit compounds analogous to ROP18 pharmacophore were passed through the Specs. After two rounds of docking, 25 out of 100 hits were identified as belonging to two main scaffold types: phthalimide ring structure, thiazole ring and styrene structure. Additionally, the screen also identified 13 inhibitors with distinct scaffold types. The docking models and SAR analysis demonstrated that these hits could engage in multiple hydrogen bonds, salt bridges halogen bonds, and hydrophobic interactions with ROP18, and para-position halo substituents on the benzene ring may enhance their affinity scoring.

conclusionsA pharmacophore against the ROP18 ATP-binding pocket was successfully constructed, and 25 representative inhibitors from 15 scaffold clusters were screened using the Specs database. Our results provide useful scaffold types for the chemical inhibition of ROP18 or alternative conformations to develop new anti-toxoplasmosis drug leads.

Indexed as

Molecular Docking SimulationDrug DesignProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtozoan ProteinsSoftwareStructure-Activity RelationshipToxoplasmaVirulenceVirulence FactorsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtozoan ProteinsROP18 protein, Toxoplasma gondiiVirulence FactorsCompetitive inhibitorsPharmacophore modelROP18Toxoplasma gondiiVirtual screening

Identifiers

PMID30867024
PMCPMC6416898
OpenAlexW2947702835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.